Figure 2.

SVR12/24 in the effectiveness population analysis. Percentage of patients achieving SVR12/24 in the effectiveness population after being treated with SOF/VEL for 12 weeks without ribavirin, stratified by (A) HCV genotype (B) fibrosis stage (C) intravenous drug use, PPI use at baseline and treatment history. ^†The definition of former drug use varied between cohorts with respect to timing and this level of detail was not available for most patients. ^‡Information on patients achieving SVR12/24 by PPI use at baseline was not available in one cohort, and thus patients from this cohort (n = 183) were not considered in this subgroup analysis. ^§Patients were treated with PEG‐IFN + RBV (± PI boceprevir, telaprevir, simeprevir). F, fibrosis; GT, genotype; PEG‐IFN, pegylated interferon; PI, protease inhibitor; PPI, proton pump inhibitor; RBV, ribavirin; SOF/VEL, sofosbuvir/velpatasvir; SVR12/24, sustained virological response 12/24 weeks after the end of treatment